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We introduce neutron-encoded (NeuCode) amino
acid labeling of mice as a strategy for multiplexed
proteomic analysis in vivo. Using NeuCode, we
characterize an inducible knockout mouse model
of Bap1, a tumor suppressor and deubiquitinase
whose in vivo roles outside of cancer are not well
established. NeuCode proteomics revealed altered
metabolic pathways following Bap1 deletion,
including profound elevation of cholesterol biosyn-
thetic machinery coincident with reduced expres-
sion of gluconeogenic and lipid homeostasis
proteins in liver. Bap1 loss increased pancreatitis
biomarkers and reduced expression of mitochon-
drial proteins. These alterations accompany a
metabolic remodeling with hypoglycemia, hyper-
cholesterolemia, hepatic lipid loss, and acinar cell
degeneration. Liver-specific Bap1 null mice pre-
sent with fully penetrant perinatal lethality, severe
hypoglycemia, and hepatic lipid deficiency. This
work reveals Bap1 as a metabolic regulator in
liver and pancreas, and it establishes NeuCode as
a reliable proteomic method for deciphering in vivo
biology.This is an open access article under the CC BY-NINTRODUCTION
Mass spectrometry (MS) proteomics is an essential tool for
studying proteins and post-translational modifications (PTMs)
that are dysregulated in human disease (Lawrence et al., 2015).
While mouse models are the primary systems for emulating hu-
man disease in vivo (Cheon and Orsulic, 2011), the quantitative
MS toolkit for in vivo studies is limited.
In mice, stable isotope labeling of mammals (SILAM) is a gold
standard quantitative method (Geiger et al., 2013; Kr€uger et al.,
2008; McClatchy and Yates, 2008; Wu et al., 2004). In SILAM,
control mice are fed isotopically labeled amino acids to create
heavy protein samples (Zanivan et al., 2012). Labeled reference
samples are mixed equally with unlabeled samples and quanti-
fied using liquid chromatography-tandem mass spectrometry
(LC-MS/MS) (Zanivan et al., 2013). SILAM enables accurate
quantitation with a large dynamic range without suffering from
the ratio compression seen in isobaric tagging. In addition,
SILAM yields more labeled protein than other methods and
permits sample mixing before digestion and enrichment, facili-
tating accurate quantitation of low-abundance analytes. How-
ever, SILAM is normally performed as duplex quantitation and
is used sparingly for practical reasons (Kr€uger et al., 2008). For
instance, complete protein labeling is required, because unla-
beled peptides from a heavy reference sample overlap with
and artificially augment the signal intensity of light peptides
(Kr€uger et al., 2008); however, full labeling is costly and takesCell Reports 16, 583–595, July 12, 2016 ª 2016 583
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Figure 1. NeuCode SILAM Allows Protein Quantification from
Partially Labeled Mouse Tissues
(A) Schematic comparing partial labeling in SILAM with NeuCode SILAM.
In SILAM, a 50% labeled peptide (red) from a ‘‘heavy’’ mouse will have an
unlabeled counterpart (dark gray) that overlaps in mass with an unlabeled
peptide (light gray) from the ‘‘light’’ mouse. NeuCode uses heavy-to-heavy
ratios (blue to red) and ignores unlabeled peptides.
(B) In 4-plex NeuCode, mice are labeled with K602, K521, K440, or K080, tissues
are harvested, and protein lysates are equally mixed for MS analysis. During
MS, a low-resolutionMS1 scan at 30,000 (dotted line) is performed and used to
trigger data-dependent tandem mass spectrum (MS2). Both light and heavy
features can be observed due to partial labeling. During MS2 acquisition, a
high-resolution MS1 scan (480,000) resolves closely spaced NeuCode iso-
topologues (colored peaks). An isotopologue area under the curve signal is
used to quantify peptide abundance.several months. Despite its shortcomings, there is considerable
demand for in vivo labeling to study mouse models of disease
(Rayavarapu et al., 2013; Zanivan et al., 2013).
Recently, we developed neutron-encoded (NeuCode) lysine
isotopologues differing in mass by 6 to 36 mDa for multiplexed
metabolic labeling (Hebert et al., 2013; Merrill et al., 2014;
Rhoads et al., 2014). NeuCode experiments simultaneously
compare up to four heavy labeled protein samples and ignore
unlabeled peptides, thus obviating the need for complete label-
ing (Rose et al., 2013). Applying NeuCode inmammals (NeuCode
SILAM) should offer increased multiplexing and significantly
shorter in vivo labeling times, so long as isotopologue incorpora-
tion rates are equivalent.
Brca1-associated protein 1 (Bap1) is a deubiquitinating
enzyme whose loss of function is associated with multiple hu-
man cancers (Carbone et al., 2013; Harbour et al., 2010; Testa
et al., 2011; Wiesner et al., 2011). Bap1 knockout is embryonic
lethal in mice, and its conditional deletion triggers myelopro-
liferation, splenomegaly, and thrombocytopenia (Dey et al.,
2012). Bap1 is ubiquitously expressed (Lattin et al., 2008), but
its roles outside the hematopoietic system and cancer have
not been well studied. As part of a chromatin-associated com-
plex, which includes Hcfc1, Ogt, Asxl1/2, Foxk1/2, and Kdm1b
(Dey et al., 2012; Misaghi et al., 2009; Scheuermann et al.,584 Cell Reports 16, 583–595, July 12, 20162010; Yu et al., 2010), Bap1 influences histone dynamics by deu-
biquitinating histone 2A (Scheuermann et al., 2010). Recent
studies link Bap1-interacting proteins tometabolic homeostasis.
Mice lacking Asxl2 are hyperglycemic with lipodystrophy and os-
teopetrosis (Izawa et al., 2015). Ogt and Hcfc1 influence nutrient
homeostasis by glycosylating substrate proteins in response
to glucose levels and regulating transcriptional pathways (Ma
and Hart, 2013; Ruan et al., 2012). These findings suggest that
Bap1 may also regulate metabolic homeostasis.
Here, we introduce NeuCode SILAM as a tool for deciphering
mammalian biology in vivo. We show that NeuCode isotopo-
logues incorporate at similar rates in mice without phenotypic
consequences and that accurate quantitation can be achieved
within days in some tissues. NeuCode SILAM analyses of
BAP1 knockout revealed substantial dysregulation of metabolic
pathways. In vivo metabolic studies support Bap1’s involvement
in lipid and glucose homeostasis. Together, our findings impli-
cate Bap1 inmetabolic regulation and establish NeuCode SILAM
as a promising tool for deciphering in vivo mammalian biology.
RESULTS
NeuCode Expedites Mammalian Metabolic Isotope
Studies
In SILAM, labeling is achieved by feeding mice a lysine-deficient
diet supplemented with a heavy lysine isotope that incorporates
into proteins over time. Unlike cell culture studies in which
complete labeling can be achieved within days, >95% labeling
of proteins in tissues requires months and is only achieved in
second-generation pups (from labeled mothers) (Kr€uger et al.,
2008). Whereas partial labeling is appealing for pragmatic rea-
sons, complete labeling is strongly preferred because light signal
from incompletely labeled samples convolutes measurements.
For example, if a partially labeled (e.g., 50% heavy) protein sam-
ple is equally mixed with a light protein sample, MS analysis
would yield a heavy-to-light ratio of 1:3 instead of the desired
1:1 (Figure 1A). This artifact is difficult to correct, because incor-
poration rates are protein and tissue dependent. Given that fully
labeled SILAM tissues are costly, commercially available only for
selected strains, and currently limited to 2-plex comparisons, a
strategy that overcomes these limitations would have great
value.
We reasoned that NeuCode offers an opportunity to shorten
in vivo labeling time compared to traditional SILAM, because
NeuCode experiments compare labeled protein to labeled pro-
tein. In a NeuCode experiment, light peptides are ignored during
quantification, and the equallymixed, partially labeled (e.g., 50%)
heavy samples yield the desired 1:1 peptide ratios (Figure 1A). So
long as incorporation has occurred, and the incorporation rate of
one isotopologue is comparable to that of another, complete la-
beling is not necessary. Considering newly synthesized lysine
isotopologues, 4-plex NeuCode is possible, accommodating
multiple conditions within an analysis (Figure 1B).
NeuCode Lysine Isotopologue Labeling Kinetics
To test whether NeuCode can shorten SILAM labeling, we as-
sessed the incorporation rates of K602 and K080 isotopologues,
which differ in mass by 36 mDa. To refer to these isotopologues,
we define a nomenclature: letter denotes amino acid, first digit
denotes 13C count, second digit denotes 2H count, and third digit
denotes 15N count. The heaviest lysine isotopologue, K080, is of
special interest, because every usable position is deuterated.
High deuterium content could be a concern given that its smaller
atomic radius (compared to hydrogen) may induce physiological
effects or alter labeling (Katz et al., 1962).
We fed 10-week-old male C57BL/6J mice customized K000,
K602, or K080 diets for 3, 10, 20, or 30 days (Figure 2A). At each
interval, three mice from the K602 and K080 groups were sacri-
ficed and nine tissues were collected (Figure 2A; Table S1).
Mice fed isotopologue-containing diets appeared to be as active
as controls, with food consumption (Figure S1A) and body
weights (Figure S1B) indistinguishable from those of the control
group (p > 0.2, Welch’s t test).
To assess whether isotopologues incorporate at similar rates,
proteins were extracted from each tissue or time point (108 total
samples), digested with LysC, and analyzed by high-resolution
nano-liquid chromatography tandem mass spectrometry (nLC-
MS/MS). Isotope incorporation for each protein was calculated
by dividing the intensity of the heavy feature by the summed in-
tensity of heavy and light (Figure 2A, % labeling). Figure 2B
shows label incorporation by protein in each tissue as a function
of diet and days of labeling. We observe broadly distributed
incorporation rates across the tissues, likely due to reagent avail-
ability and protein turnover rates (McClatchy and Yates, 2008).
For example, the intestine labels quickly 40% within 3 days,
while the muscle takes 30 days to reach 50% labeling. Tis-
sues with slow mean incorporation (e.g., muscle and brain)
exhibit a broader distribution of lysine incorporation (Figure 2B).
We next plotted incorporation by protein and observed that iso-
topologues displayed similar rates across all tissues (Figure 2C),
with only 8 of 19,316 proteinmeasurements differing significantly
between isotopologues (false discovery rate < 0.01, t test with
Bonferroni correction, n = 3 biological replicates). We conclude
that incorporation of K602 and K080 is nearly identical.
NeuCode SILAM Quantitative Performance
Having surveyed labeling kinetics, we next sought to determine
the shortest labeling time required for accurate quantitation.
Peptides from the preceding study were mixed in 1:1, 5:1, and
10:1 (K602:K080) ratios for each of four time points (Figure 2A,
ratios). Tissues exhibiting low (brain), medium (liver), and high (in-
testine) incorporation were analyzed, comprising 36 nLC-MS/
MS experiments (Figure 2D; Table S2). Impressively, within
3 days of labeling, 84% of identified intestinal peptides reported
measurements within ±15% of the expected ratio (Figure 2D). In
liver, we quantified 85% of detected peptides after 10 days of
labeling, when the average protein is 60% labeled (Figure 2D).
Slow incorporating tissues, such as the brain, require longer
labeling periods. After 10–20 days of labeling, brain proteins
measured in the 10:1 sample differ by >25% from the expected
value; however, labeling for 30 days results in 80% of identi-
fied peptides being accurately quantified (±15%) (Figure 2D).
These data describe a relationship between lysine incorpora-
tion and the percentage of quantifiable peptides, with increased
mean incorporation improving quantitation (Figure S1C). In gen-
eral, a mean lysine incorporation of 50% enables quantitation of>80% of identified peptides. From these data, we conclude that
a subset of tissues can be accurately quantified after just 10 days
of labeling, while labeling for 20–30 days ensures accurate quan-
titation more broadly.
NeuCode SILAM Reveals Altered Metabolic Pathways
after Bap1 Deletion
Loss-of-function mutations in Bap1 are frequently observed in
cancer (Carbone et al., 2013), but pathways regulated by Bap1
in normal tissues remain unstudied. To examine these pathways
in vivo, NeuCode SILAM isotopologues with 12 mDa spacing
(K602/K521/K440/K080) (Figure 1B) were used to label tamoxifen-
inducible Cre-expressing Bap1wt/wt,Rosa26.creERT2+ (Bap1wt)
and Bap1fl/fl,Rosa26.creERT2+ (Bap1ko) mice. We projected
that 3 weeks of NeuCode labeling would permit accurate quan-
titation in most tissues (Figure 2); hence, three Bap1ko and three
Bap1wt mice were labeled for 21 days (Figure 3A). A matching
set of six mice were fed matching K000 chow to control for isoto-
pologue effects and increase replicates for other measurements.
After 10 days of labeling, mice were subjected to a 5-day series
of tamoxifen injections to delete Bap1. After 21 days of labeling,
the mice were sacrificed and tissues were harvested for RNA
and proteomic analysis. During the study, most mice consumed
comparable amounts of chow (Figures S2A and S2B). One
Bap1ko mouse labeled with K080 consumed less food after
Bap1 deletion and was sacrificed a day early due to hunched
posture and lethargy, a phenotype sometimes observed in
Bap1ko mice. Bap1 mRNA expression was reduced 80%–95%
in liver, spleen, and pancreas, while deletion in other tissues was
less effective (50%–80%) (Figures 3C and S3). Because overex-
pression of Bap1 in liver canmodestly enhance gluconeogenesis
(Ruan et al., 2012), we measured serum glucose at intervals
from the start of tamoxifen injections. Bap1ko mice became
significantly hypoglycemic on the day following the last tamox-
ifen injection (i.e., day 1) (Figure 3B). An independent cohort of
unlabeled Bap1ko mice also exhibited hypoglycemia at day 7,
signifying a consistent and necessary role for Bap1 in maintain-
ing euglycemia (Figure S4).
We performed NeuCode proteomic profiling on spleen,
because Bap1 dramatically influences hematological composi-
tion (Dey et al., 2012), and on liver and pancreas, because they
are closely tied tometabolic homeostasis. Lysates frombiological
replicates of each tissue were mixed in 4-plex or 2-plex formats,
digested with LysC, and fractionated for nLC-MS/MS analysis
(Figure 3A). In aggregate, 7,646proteinswere quantified in at least
one tissue (Table S3). Sets of significantly changing proteins show
minimal overlap among tissues, a result that suggests Bap1 is a
context-dependent regulator of multiple pathways (Figure 3D).
We performed protein set enrichment analyses of gene
ontology (GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways using the Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) (Figures 3E–3G) (Huang
da et al., 2009). In spleen, Bap1 deletion reduced cell-cycle pro-
teins (p = 6.2e-20), consistent with pancytopenia often observed
in myelodysplastic disorders (Figure 3E) (Foran and Shammo,
2012). In pancreas, Bap1 knockout elevated Reg family pancrea-
titis markers (Graf et al., 2002) and significantly reduced mito-
chondrial protein expression (p = 2.3e-4) (Figure 3F). PancreaticCell Reports 16, 583–595, July 12, 2016 585
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Figure 2. Labeling Efficiency and Accuracy of NeuCode SILAM
(A)Micewere labeledwith eitherK602 orK080 for 3–30days. Proteins extracted fromnine tissueswere LysCdigestedand analyzed byMS. Light and heavypeptides
are quantified to assess percent labeling. K602 and K080 peptide samples from some tissues were also mixed at defined ratios to assess NeuCode accuracy.
(B) Heavy lysine percentage incorporation is plotted by tissue and labeling time. Boxplots represent the average of n = 3 animals per protein (K602, blue; K080, red).
Box edges are the 25th and 75th percentiles, with the median protein shown. Whiskers extend to the 1.53 interquartile range, and outliers are plotted as circles.
(C) Correlation plots of K602:K080 labeling for a representative biological replicate from each time point and tissue.
(D) Proteins frommice fed K602 or K080 were mixed in defined ratios (1:1, 5:1, and 10:1) for intestine, liver, and brain. Expected ratios are signified by dotted lines,
and measured ratios are displayed as boxplots as in (B).
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Figure 3. NeuCode SILAM Analysis 7 Days Following Bap1 Deletion
(A) Bap1ko NeuCode experimental design. Micewere labeled 21 days with four NeuCode diets (K602, K521, K440, and K080). During labeling, micewere treatedwith
tamoxifen (tam) for 5 days to delete Bap1. Day 0 is the fifth and final tam injection (day 14 of labeling). Liver, pancreas, and spleen were harvested, and protein
lysates were mixed as 4-plex and 2-plex. High-resolution (480,000) MS1 scans reveal NeuCode-labeled peptides, which are quantified by area under the curve.
(B) Glucose measurements during (day < 0) and after (day > 0) 5 daily tam injections. *p < 0.05; **p < 0.01 in two-tailed unpaired t test. n = 6 per group.
(C) Bap1 mRNA measured by qPCR with primers spanning the deleted exons. n = 6 per group.
(D) Number of proteins changing more than 1.5-fold with a nominal p < 0.05 following Bap1 deletion.
(E–G) Volcano plots of all proteins using log2 ratios and nominal p values for spleen (E), pancreas (F), and liver (G). Significantly enriched protein sets and individual
proteins referred to in the text are colored and labeled.acinar cells harbor large numbers of mitochondria to power
exocrine output (Petersen, 2012). From these results, we hypoth-
esized that Bap1 is involved in acinar cell maintenance. In Bap1ko
liver, acute phase inflammation biomarkers, including Hp, Hamp,Orm1/2, and Mt1/2, were elevated, suggesting an ongoing stress
or damage response (Gruys et al., 2005). The hexose (p = 0.035)
and glucose (p = 0.053) metabolic pathways were also repressed
in liver. Fbp1, a key enzyme in gluconeogenesis, was decreasedCell Reports 16, 583–595, July 12, 2016 587
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Figure 4. Proteomic and Pathological Characterization of BMC-Bap1ko Mice
(A) Schematic of bone marrow rescue experiments and NeuCode labeling.
(B) Platelet measurements. n = 3 mice per group. Error bars, SEM.
(C) Time course of glucose measurements following Bap1 deletion in BMC mice. n = 11 wild-type (WT) female, 10 knockout (KO) female, 9 WT male, 9 KO male
mice. *p < 0.001, two-tailed unpaired t test.
(D) Proteins changing >2-fold with nominal p < 0.05 in NeuCode SILAM data from each tissue following 3 months of Bap1 knockout, with the final 3 weeks being
fed NeuCode diets. n = 3 WT and KO. WAT: White adipose tissue, BAT: Brown adipose tissue.
(E) Comparison among all proteins identified in NeuCode SILAM experiments in liver at day 7, from Figure 3, and at day 90 post-Bap1 deletion. Select proteins are
labeled.
(F) Log2 KO:WT ratios of enriched K-GG (ubiquitinated) peptides from day 7 Bap1ko NeuCode livers are plotted against liver total protein ratios from the same
samples analyzed in Figure 3F. Histone H2A isoforms and outer membrane mitochondrial proteins Vdac1/2/3 andMaob are highlighted. Residue numbers derive
from UniProt and include the start methionine.nearly 2-fold upon Bap1 deletion (Figure 3G). Other glycolytic and
gluconeogenic regulators, including Pklr and Aldob, were also
depleted and could contribute to the hypoglycemia observed.
While lipid pathways were not broadly changed, key lipid chaper-
ones Fabp1/2/5 and Plin2 were markedly reduced. Most strik-
ingly, the cholesterol biosynthetic pathway was significantly
elevated (p = 3.6e-13) in Bap1ko liver. Taken together, our
NeuCode proteomic analyses link Bap1 to metabolic and tissue
damage pathways in liver and pancreas, providing key hypothe-
ses for in vivo experimentation.
Bap1 Regulates theMetabolic Proteome Independent of
Hematopoietic Defects
In addition to hypoglycemia, our proteomic data suggest that
Bap1ko mice may suffer from eventual liver and pancreas588 Cell Reports 16, 583–595, July 12, 2016damage, as well as lipid and cholesterol mismanagement.
However, these hypotheses are difficult to test in Bap1ko mice
due to myeloid transformation. Bap1ko mice become lethargic
and require euthanization within weeks, precluding analysis
of later-developing phenotypes such as tissue damage. One
Bap1ko mouse in our NeuCode study was sacrificed a day early
for this reason. Hematopoietic defects might indirectly influence
the proteomic markers of metabolic rewiring and the damage
observed in liver and pancreas.
To exclude the hematopoietic role of Bap1, we rescued
Bap1komicewith bonemarrow fromBap1wt/wt donormice. After
hematopoietic reconstitution for 5 weeks, Bap1 was deleted by
tamoxifen injection (Figure 4A). Bone marrow chimeric Bap1ko
mice (i.e., BMC-Bap1ko) exhibited normal platelet counts
compared to matched wild-type tamoxifen-treated controls
(Figure 4B). Serum glucose measurements in male and female
mice revealed significant hypoglycemia by day 7 (Figure 4C), es-
tablishing that this metabolic parameter is not due to hematopoi-
etic Bap1 deletion. BMC-Bap1ko mice survive >3 months, indi-
cating that Bap1 expression in the adult hematopoietic system is
necessary for long-term viability.
To assess whether similar proteomic pathways are altered
in BMC-Bap1ko mice, tamoxifen injections were performed
5 weeks following bone marrow reconstitution. BMC-Bap1ko
mice were aged for 9 weeks and then NeuCode labeled for
3 weeks (Figure 4A). Mice ate similar quantities of labeled food
(Figure S5) and did not appear to be affected by the isotopologue
diet. We focused our analyses on liver and pancreas, which
exhibit effective Bap1 deletion and the most significant proteo-
mic changes (Figures 4D and S3). In liver, we observed a similar
proteomic signature to non-BMC mice 7 days after knockout,
with elevation of cholesterol biosynthesis and downregulation
of gluconeogenesis and lipid chaperone proteins (Figure 4E).
Bap1 deletion in liver therefore affects metabolism indepen-
dently of the hematopoietic system.
In pancreas, the proteomic signature observed 12 weeks after
Bap1deletionmirroredchanges from thenon-BMCday7dataset
(Figure S6). In both datasets, mitochondrial proteins were
reduced and pancreatitis markers, such as Reg2 and Reg3,
were upregulated. Effect sizes increased after 12 weeks, sug-
gesting aprogressive transformationof thepancreatic proteome.
Strikingly, there was substantial loss of ribosomal structural sub-
units, which was not observed 7 days post-deletion (Figure S6).
Bap1 Modulates Histone H2A and Mitochondrial
Ubiquitination in Liver
While Bap1 regulates histone H2A ubiquitination in vitro
(Scheuermann et al., 2010), its activity toward distinct H2A iso-
forms in liver has not been described. Ubiquitinated peptides
can be enriched using antibodies against the tryptic, diglycine
remnant (K-GG) and quantified by MS (Kim et al., 2011). We
used NeuCode SILAM to analyze K-GG peptides in 4-plex
and 2-plex liver samples at day 7 post-deletion. K-GG peptide
ratios were compared to their corresponding protein level ratios
(Figure 3G) for peptides quantified in at least two biological
replicates (Figure 4F; Table S5). Bap1 loss elevated ubiquitina-
tion of the canonical H2A K119 site nearly 2-fold. The alterna-
tive H2AX isoform exhibited increased ubiquitination at K119
and K120, but not K128, in Bap1ko liver. The corresponding
K116 site on macro-histone H2AY ubiquitination increased
1.5-fold without a change in total protein abundance. Bap1
deletion in liver also increased ubiquitination of select outer
mitochondrial membrane proteins, including the three Vdac
isoforms and Maob (Figure 4F). Although the exact roles of
Vdac and Maob ubiquitination in liver metabolism are
unknown, they can be indicators of mitochondrial stress
(Narendra et al., 2010).
Bap1 Loss Causes Defects in Liver Gluconeogenesis
and Lipid Homeostasis
To assess whether our proteomic results predicted metabolic
changes in vivo, we tested serum biomarkers in fed and fasted
cohorts of BMC-Bap1wt and BMC-Bap1komice 2 and 12weekspost-deletion (Figures 5A and 5B). As predicted, BMC-Bap1ko
mice display high cholesterol at both early and late time points.
Surprisingly, after 2 weeks, cholesterol appears to be higher
only in the fasting state (Figure 5A). In the proteomics data
from 12 weeks post-deletion, the rate-limiting enzyme for ketone
body biosynthesis, Hmgcs2, was reduced nearly 2-fold in BMC-
Bap1ko (Table S4). Consistent with this, fasting ketogenesis was
severely blunted in BMC-Bap1ko mice (Figure 5A).
As predicted by proteomic signatures of liver acute phase
response, damage markers ALT and AP were elevated at
2 weeks and progressed higher by 12 weeks post-deletion. Total
serum protein was reduced at 12 weeks but not at 2 weeks,
signifying progressive liver malfunction (Figure 5B). Frozen sec-
tions from BMC-Bap1ko livers appeared to be histologically
normal 2 weeks post-deletion (Figure 5C) but revealed disorga-
nized hepatic plates, scattered pyknotic nuclei (signifying dying
hepatocytes), and hypereosinophilic staining with diminished
vacuolation after 12 weeks (Figure 5C). Significant immune cell
infiltration, typical of hepatitis, was not observed.
Our proteomic results posit that Bap1 is required for preserving
pancreatic acinar cell functions. Two weeks after Bap1 deletion,
acinar cells were notably larger and hypereosinophilic. After
12 weeks, acinar cells degenerated severely, leaving isolated is-
lets and instances of apparent ductal hyperplasia (Figure 5D).
Pancreas histology data at 12 weeks post-deletion aligned well
with NeuCode SILAM, as acinar-enriched mitochondrial and ri-
bosomal proteins were conspicuously diminished in Bap1ko
(Figure S6).
We sought to further refine our understanding of Bap1 function
using a battery ofmetabolic assays. To avoid complications from
later-developing liver damage, pancreatitis, and myeloprolifera-
tion, experiments were performed on BMC-Bap1ko mice within
2 weeks of deletion, when livers appeared to be normal by histol-
ogy (Figure 5C) and liver damage markers showed only modest
elevation (Figure 5A). Despite abnormal acinar cell architecture,
the islets appeared to be normal by histology and insulin staining
(Figure 6A). Circulating insulin was significantly lower in fasting
BMC-Bap1ko animals, possibly due to increased insulin sensi-
tivity or hypoglycemia, but insulin release after glucose challenge
was similar to controls (Figure 6B). Normal insulin staining and
release in BMC-Bap1ko mice indicate that changes in insulin
dynamics are not the primary factor dysregulating glucose
homeostasis.
Consistent with increased insulin sensitivity, BMC-Bap1ko
animals were more glucose tolerant after fasting (Figure 6C). In
a pyruvate tolerance test, BMC-Bap1ko animals were severely
blunted in gluconeogenic capacity (Figure 6D). Recently, the
master metabolic regulator Pgc1a was reported to be stabilized
by Bap1-mediated deubiquitination in 293T cells. Pgc1a protein
was below the detection limit for MS or western blotting in
NeuCode liver samples. Surprisingly, Pgc1amRNAwas reduced
85% in fed liver but still induced during fasting (Figure S7A). We
did not observe blunted fasting induction of the Pgc1a target and
rate-limiting gluconeogenesis enzyme, Pck1 (Figure S7B). G6pc
was modestly induced by fasting but did not reach statistical
significance (Figure S7C). These data suggest Bap1 regulation
of gluconeogenesis and Pgc1a are likelymore complex than pre-
viously appreciated.Cell Reports 16, 583–595, July 12, 2016 589
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Figure 5. Serum Chemistry and Pathology of BMC-Bap1ko Mice
(A and B) Serum chemistry for BMC-Bap1 mice 2 or 12 weeks post-deletion. Fed denotes ad libitum feeding, and fasted denotes a 16 hr overnight fast. (A) At
2 weeks, Wt-fed (n = 5), Wt-fast (n = 12), Ko-fed (n = 5), and Ko-fast (n = 14). (B) At 12 weeks, Wt-fed (n = 12), Wt-fast (n = 12), Ko-fed (n = 14), and Ko-fast (n = 14).
*p < 0.001, unpaired two-tailed t test.
(C and D) H&E staining of (C) pancreas and (D) liver of BMC-Bap1wt and BMC-Bap1ko mice 2 and 12 weeks post-deletion.During fasting gluconeogenesis, the liver relies on lipid mobi-
lization and fatty acid oxidation for fuel in place of glucose.
Because our data revealed decreased lipid chaperones in590 Cell Reports 16, 583–595, July 12, 2016Bap1komice (Figure 3G), we stained for lipids in liver (Figure 6E).
Similar to mice lacking Fabp1 and Plin5 (Newberry et al., 2003;
Wang et al., 2015), two proteins downregulated in Bap1ko livers,
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Figure 6. Metabolic Characterization of
BMC-Bap1ko Mice
(A) Insulin staining of BMC-Bap1wt and BMC-
Bap1ko pancreas 2 weeks post-deletion. Repre-
sentative image from n = 3 mice.
(B) Insulin release assay. Mice were fasted 12 hr,
and serum insulin concentrations were measured
at times after glucose injection. Error bars, SEM.
*p < 0.01. Replicated in two independent cohorts.
(C) Glucose tolerance assay. Mice were fasted
6 hr, and serum glucose was measured at the
times after glucose challenge. Error bars, SEM. *p<
0.001. Replicated in three independent cohorts.
(D) Pyruvate tolerance assay. Mice were fasted
overnight (16 hr), and serum glucose was
measured at the times after pyruvate injection.
Error bars, SEM. *p < 0.001. Replicated in three
independent cohorts.
(E) Oil red O staining of BMC-Bap1wt and BMC-
Bap1ko ad libitum fed or fasted 12 hr. Represen-
tative of n = 3 mice per condition.
(F) BMC-Bap1wt and BMC-Bap1ko mice were
fed high-fat chow for the indicated times starting
2 weeks post-deletion. *p < 1e-10.BMC-Bap1ko mice had significantly lower liver lipid stores dur-
ing fasting, indicating that Bap1 is essential for limiting lipid utili-
zation, uptake, or production. Consistent with Bap1 regulating
lipid metabolism, BMC-Bap1ko mice were completely resistant
to weight gain on a high-fat diet for up to 6 weeks (Figure 6F).
Liver-Specific Bap1 Deletion Causes Perinatal Lethality
with Hypoglycemia and Hepatic Hypolipidemia
The metabolic alterations observed in adult BMC-Bap1ko
mice may be shaped by multiple organs. Because pancreatic
islets were normal (Figures 6A and 6B), we reasoned that Bap1
functions primarily in liver to control gluconeogenesis and lipid
homeostasis. Liver-specific Bap1ko mice (Bap1fl/fl;Alfp.cre+)
expired within 48 hr of birth. Label-free proteomics on 12 hr
post-natal livers revealed key gluconeogenic enzymes G6pc
and Fbp1 were significantly downregulated (Figure 7A). As in
adults, Bap1 loss did not suppress Pck1 (Figure 7A) but did
significantly reduce Plin and Fabp proteins (Figure 7B). Key
cholesterol biosynthesis enzymes, including Hmgcs1 and
Hmgcr, were also elevated (Figure 7C). Overall, the metabolic
protein alterations observed in adult Bap1ko animals are simi-
larly perturbed in Bap1fl/fl;Alfp.cre+ neonates.
Liver gluconeogenesis is essential for neonates to survive until
suckling (Grijalva and Vakili, 2013). In concert with low expres-
sion of gluconeogenic enzymes, liver-specific Bap1ko mice
were profoundly hypoglycemic within hours after birth (Fig-
ure 7D), suggesting that these neonates fail to activate gluconeo-
genesis. We observed moderate hypoglycemia in heterozygous
Bap1wt/fl;Alfp.cre+ neonates, indicating a dose effect of Bap1
protein (Figure 7D). Bap1fl/fl;Alfp.cre+ liver sections showed
less vacuolation than wild-type tissues (Figure 7E). Occasional
shrunken nuclei were also observed by histology, but post-natal
cleaved caspase-3 levels were indistinguishable from controls,
indicating the absence of overt liver damage that may indirectly
cause metabolic distress (Figure 7F). Lipids and glycogen were
both depleted in Bap1fl/fl;Alfp.cre+ neonatal liver (Figures 7Gand S7D). In prenatal livers at embryonic day (E) 18.5, we
observed a striking Bap1 dose-dependent loss of lipids similar
to that seen after birth (Figure 7G). Bap1 expression is therefore
critical for hepatic lipid management in preparation for post-par-
tum fasting (Figure 7G). Taken together, our data show that Bap1
is essential for maintaining lipid and glucose homeostasis in the
neonatal and adult mouse liver.
DISCUSSION
This work demonstrates the effectiveness of NeuCode prote-
omics for studying genetically engineered mouse models and
reveals a prominent role for Bap1 in metabolic homeostasis.
Bap1 has received considerable attention for its mutational
spectrum in cancer (Carbone et al., 2013; Harbour et al., 2010;
Testa et al., 2011; Wiesner et al., 2011). Bap-interacting proteins
are consistent among cell types and tissues (Dey et al., 2012;
Machida et al., 2009; Misaghi et al., 2009; Scheuermann et al.,
2010; Yu et al., 2010), with several showing roles inmetabolic ho-
meostasis (Bond and Hanover, 2015; Iwata et al., 2013, 2015).
Asxl1 and Asxl2 are obligate subunits, which control Bap1 activ-
ity and proposed to differentially regulate nuclear receptors Lxr,
Ppara, and Pparg (Park et al., 2011, 2014). Asxl2 null mice show
impairment of lipogenesis in adipose tissue and Pparg-medi-
ated activation of osteoclastogenesis (Izawa et al., 2015). It will
be interesting to determine whether Asxl2 functions alone or
through Bap1 to mediate these effects. Asxl2 null mice were
not assessed for liver hypolipidemia but were surprisingly hyper-
glycemic, suggesting differential regulation of glucose pathways
by Bap1 and Asxl2.
Bap1 overexpression in liver slightly enhances gluconeogen-
esis, possibly by stabilizing Pgc1a (Ruan et al., 2012). We found
that Bap1 deletion significantly reduced Pgc1amRNA, adding a
new layer of regulation. However, unlike Pgc1a null animals,
Bap1ko mice are hypoglycemic in the fed state, not just during
fasting, and display significantly increased serum cholesterol,Cell Reports 16, 583–595, July 12, 2016 591
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Figure 7. Liver-Specific Bap1 Deletion Causes Neonatal Mortality with Metabolic Defects
(A–C) Label-free proteomics of gluconeogenic, lipid chaperone, and cholesterol biosynthesis enzyme expression in the neonatal liver (12–24 hr postnatal). n = 3
mice. Error bars, SEM. *p < 0.05.
(D) Blood glucose recorded 1–4 hr post-partum for each indicated genotype. *p < 0.01. **p < 1e-8.
(E) H&E staining of frozen neonatal liver section 6 hr post-partum.
(F) Cleaved caspase-3 staining of liver frozen sections 12 hr post-partum.
(G) Frozen sections of liver stained with oil red O (red) demonstrating intra-hepatic lipid of E18.5 embryos and post-natal day (P) 0 neonates (12 hr post-partum)
with the designated genotypes.liver hypolipidemia, and pancreatic abnormalities (Lin et al.,
2004). In addition, in contrast to Bap1komice,micewith reduced
Pgc1a expression specifically in liver exhibit higher hepatic lipid
content after fasting (Estall et al., 2009). Diminished Pgc1a
signaling likely contributes to some of the observed phenotypes
in Bap1ko mice, but Bap1 likely modulates metabolism by
additional means. In accord with this hypothesis, Bap1 deletion
significantly increases ubiquitination on multiple H2A isoforms
and mitochondrial proteins in liver. One H2A variant exhibiting
increased ubiquitination, H2AY (also known as macro-H2A),
influences gene expression of Fabp1 and Hmgcr in cultured
hepatocytes (Pazienza et al., 2014). Deleting the H2AY in mice
partially protects against high-fat feeding and epigenetically ac-
tivates the promoters of lipogenic genes (Pehrson et al., 2014;
Podrini et al., 2015).
Bap1 loss caused progressive damage to hepatocytes and
acinar cells. Mouse models of liver damage including hepatec-
tomy, drug-induced hepatotoxicity, and acute infections can
trigger hypoglycemia and hypercholesterolemia similarly to592 Cell Reports 16, 583–595, July 12, 2016Bap1 loss (Delgado-Coello et al., 2011; Inoue et al., 2004; Kho-
vidhunkit et al., 2004). However, hypoglycemia presented within
days of Bap1 deletion coincident with only modest increases in
liver damage markers and before observable liver tissue pathol-
ogy. Moreover, liver-specific Bap1ko mice display fully pene-
trant metabolic defects in the absence of tissue damage. These
results suggest a direct role for Bap1 in regulating metabolic
homeostasis.
NeuCode Lysine Isotopologue Labeling Kinetics
This work highlights the utility of 4-plex NeuCode labeling in
mammals. Key to this approach, the NeuCode lysine isotopo-
logues incorporate at similar rates and enable quantitation in
fast-incorporating tissues after only 10 days of labeling. This
reduced label consumption (>10-fold), in combination with
commercialization of isotopologue reagents, will facilitate routine
application of NeuCode SILAM. Alternatives to NeuCode,
including multiplexed SILAM with lysine isotopes with different
masses (e.g., K002, K040, and K600) may share this benefit, but
overlapping isotopic clusters and spectral complexity would
likely present major obstacles. Increasing NeuCode plexing can
also present analytical challenges. For example, 10%–15%
fewer peptides were quantified in 4-plex compared to 2-plex
NeuCode analyses. This reduction is mainly due to spreading of
the quantitative signal across four channels so that some pep-
tides fall below the required signal-to-noise threshold. Like
isobaric tagging, SILAM is more costly than using label-free
methods. Looking forward, NeuCode is suitable for studying pro-
tein turnover in vivo by pulse chase and key lysine PTMs, such as
ubiquitination. Moreover, NeuCode SILAM may be expanded to
6-plex using newly synthesized lysine isotopologues (K422 and
K341) that are available but not used in this study (Merrill et al.,
2014). In summary, we use NeuCode proteomics in vivo to
decipher roles of the tumor suppressor Bap1 in maintaining
metabolic homeostasis. Given the multifaceted links between
metabolism and cancer, this study opens avenues for exploring
crosstalk between the tumor suppressor and the metabolic
regulatory roles of Bap1.
EXPERIMENTAL PROCEDURES
Mice and Labeling
Male C57BL/6J mice (Jackson Laboratory) were used for labeling effi-
ciency studies. Floxed Bap1 mice (Bap1ko) were generated and Bap1 deleted
with tamoxifen as previously described (Dey et al., 2012). The liver-specific
deletion of BAP1 was generated by crossing Bap1fl/fl mice with the Alfp.cre
strain. For NeuCode labeling, mice were fed a customized lysine-free diet
(Harlan) combined with 1% K602, K521, K440, or K080 (Cambridge Isotope
Laboratories) for indicated times. To reconstitute bone marrow, donor cells
from Bap1wt/wt animals were injected into the tail vein of irradiated recipients
(Bap1ko or Bap1wt). Reconstituted mice were given 0.11 mg/ml polymyxin
B and 1.1 mg/ml neomycin water for 2 weeks. The Genentech Institutional
Animal Care and Use Committee approved these protocols.
Protein Preparation
Cleared protein lysate from homogenized NeuCode-labeled tissue samples
weremixed in equal amounts to provide two samples (4-plex and 2-plex) per tis-
sue. Mixed samples were reduced, alkylated, digested with either LysC or
trypsin, and desalted according to Supplemental Experimental Procedures.
Peptides were fractionated at high pH across a Gemini C18 reverse-phase col-
umn and pooled into 16 samples, which were dried for LC-MS/MS analysis.
Mass Spec Preparation
Online reverse-phase chromatographywas performed using a nanoAcquity ul-
tra-high pressure liquid chromatography (UPLC) (Waters) or Easy-nanoLC
1000 (Thermo Scientific). Peptides were eluted over a 70 min gradient using
a self-packed analytical column (75 mm internal diameter [ID], 60C, 30 cm,
130 A˚ pore size, Bridged Ethylene Hybrid C18 particles, Waters) with mobile
phase A (0.2% formic acid/5% DMSO) and mobile phase B (acetonitrile/
0.2% formic acid). Eluted peptides were analyzed on a Thermo Scientific Orbi-
trap Elite mass spectrometer. A survey scan was performed at 30,000
resolving power to identify precursors to sample for data-dependent, top 20
MS/MS. A 480,000 resolving power scan immediately followed and was per-
formed simultaneously with MS/MS scans. Precursor mass spectrum (MS1)
and MS/MS target-ion accumulation values were set to 1E6 and 5E3, respec-
tively. Dynamic exclusion was set to 45 s for25 ppmand +15 ppm around the
selected precursor. Label-free proteomics of neonate liver samples are
described in Supplemental Experimental Procedures.
Data Processing
Data reduction and searching of NeuCode data were performed with Coon
OMSSA (open mass spectrometry search algorithm) proteomic analysissoftware suite (COMPASS), as detailed in Supplemental Experimental Proce-
dures (Wenger et al., 2011). Peptides were quantified using NeuQuant (Merrill
et al., 2014). Quantified peptides were grouped into proteins using Protein
Hoarder and Procyon modules in COMPASS. Unique protein groups were
mean normalized and log2 transformed before calculating ratios and p values.
Proteins that were quantified in all six mice (three knockout and three
wild-type) with greater than 1.5-fold change (2-fold for spleen) and a nominal
p < 0.05 were input for protein set enrichment analysis by DAVID (Huang da
et al., 2009).
Ubiquitination Analysis
Sample preparation, immuno-affinity enrichment, LC-MS/MS, and data
analysis of K-GG-containing peptides was performed using 60 mg total liver
protein (4-plex, 4 3 15 mg; 2-plex, 2 3 30 mg) as previously described
(Bingol et al., 2014) with minor modifications. Namely, paired MS1 scans
at 480,000 and 30,000 resolution were collected in each duty cycle. For
searching, a variable mass on lysines of +8.0322 Da was used to account
for NeuCode labeling. Search data were analyzed as explained earlier using
NeuQuant.
Statistical Analyses
Mean values measured from animal groups were compared using unpaired
two-way Student’s t tests for all metabolic, proteomic, and qPCRmRNAmea-
surements. NeuCode proteomic data were analyzed at the protein level using
t test nominal p values and corrected by Benjamini-Hochberg for testing
multiple hypotheses where indicated.
Serum Chemistry, Histology, and Immunohistochemistry
Blood was obtained from the retro-orbital sinus under anesthesia, collected
in tubes containing K3-EDTA (hematology samples) or no additive, and
spun to collect serum (clinical chemistry samples). Standard clinical pathol-
ogy measurements are described in Supplemental Experimental Procedures.
Fed glucose was measured in the morning and fasted glucose was measured
after a 16 hr overnight fast, unless otherwise specified. For glucose and
pyruvate tolerance tests, mice were fasted 6 and 16 hr, respectively.
Pancreas and liver tissue samples were formalin fixed, paraffin embedded,
sectioned at 4 mm, and routinely stained with H&E for histopathology.
Additional sections of liver were optimal cutting temperature compound
(OCT) embedded and frozen at the time of necropsy for oil red O staining.
The antibodies used were Dako polyclonal guinea pig anti-insulin and Cell
Signaling Technology cleaved caspase-3 at a 0.06 mg/ml concentration.
Primary antibodies were detected with biotinylated goat anti-rabbit anti-
bodies (Vector Laboratories), and the reaction was visualized with a diamino-
benzidine (DAB) map detection kit (Ventana). Slides were counterstained with
hematoxylin. Tissues were evaluated for glycogen using the periodic acid-
Schiff reaction.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.096.
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